Abstract |
This article highlights a unique time in the history of hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure hepatitis C is discussed.
|
Authors | Fernando E Membreno, Jennifer C Espinales, Eric J Lawitz |
Journal | Clinics in liver disease
(Clin Liver Dis)
Vol. 17
Issue 1
Pg. 129-39
(Feb 2013)
ISSN: 1557-8224 [Electronic] United States |
PMID | 23177289
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Antiviral Agents
- Cyclosporins
- Enzyme Inhibitors
- Interferon-alpha
- Recombinant Proteins
- Viral Nonstructural Proteins
- Polyethylene Glycols
- Ribavirin
- Cyclosporine
- (melle-4)cyclosporin
- NS-5 protein, hepatitis C virus
- Cyclophilins
- peginterferon alfa-2a
- alisporivir
- SCY-635
|
Topics |
- Antiviral Agents
(therapeutic use)
- Cyclophilins
(antagonists & inhibitors)
- Cyclosporine
(therapeutic use)
- Cyclosporins
(therapeutic use)
- Drug Therapy, Combination
- Enzyme Inhibitors
(therapeutic use)
- Hepacivirus
(enzymology, genetics)
- Hepatitis C
(drug therapy)
- Humans
- Interferon-alpha
(therapeutic use)
- Polyethylene Glycols
(therapeutic use)
- Recombinant Proteins
(therapeutic use)
- Ribavirin
(therapeutic use)
- Viral Nonstructural Proteins
(antagonists & inhibitors)
|